Literature DB >> 2293208

A sensitive and specific liquid-chromatographic assay for determination of ganciclovir in plasma and urine and its application to pharmacokinetic studies in the rabbit.

M A Hedaya1, R J Sawchuk.   

Abstract

A liquid-chromatographic assay for the analysis of ganciclovir in plasma and urine is described. This assay involves the use of acyclovir, an antiviral drug structurally related to ganciclovir, as the internal standard. A two-step sample preparation method is used. After protein is precipitated with acetonitrile and the addition of diethyl ether, ganciclovir and the internal standard are back extracted into a small volume of aqueous ammonium phosphate, taking advantage of their relatively high water solubility. This isocratic method is specific and sufficiently sensitive to allow quantification of ganciclovir throughout the entire range of concentrations observed during therapeutic use of this antiviral drug. There was no interference from various over-the-counter and prescription drugs often prescribed to patients most likely to receive ganciclovir therapy. This assay was used to analyze plasma and urine samples obtained after intravenous administration of ganciclovir to rabbits. Biexponential decay of ganciclovir plasma concentration-time and urinary excretion rate-time profiles was observed, with a mean distribution half-life of 15.8 min and an elimination half-life of 96 min. The mean renal clearance, 9.0 ml/min per kg, exceeds the glomerular filtration rate in the rabbit, indicating that ganciclovir is actively secreted in the renal tubule. Similar results were obtained by determining the renal clearance at steady state during constant-rate intravenous infusion of ganciclovir.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293208     DOI: 10.1023/a:1015920023272

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function.

Authors:  J P Sommadossi; R Bevan; T Ling; F Lee; B Mastre; M D Chaplin; C Nerenberg; S Koretz; W C Buhles
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

2.  High-performance liquid chromatographic method for the determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine in human plasma.

Authors:  J P Sommadossi; R Bevan
Journal:  J Chromatogr       Date:  1987-03-06

3.  Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.

Authors:  A Erice; M C Jordan; B A Chace; C Fletcher; B J Chinnock; H H Balfour
Journal:  JAMA       Date:  1987-06-12       Impact factor: 56.272

4.  Human pharmacokinetics of the antiviral drug DHPG.

Authors:  C Fletcher; R Sawchuk; B Chinnock; P de Miranda; H H Balfour
Journal:  Clin Pharmacol Ther       Date:  1986-09       Impact factor: 6.875

5.  A competitive enzyme-linked immunosorbent assay to quantitate acyclovir and BW B759U in human plasma and urine.

Authors:  S M Tadepalli; R P Quinn; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

6.  Ganciclovir pharmacokinetics during renal impairment.

Authors:  K D Lake; C V Fletcher; K R Love; D C Brown; L D Joyce; M R Pritzker
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

7.  Efficacy and safety of two different dose levels of ganciclovir for the treatment of cytomegalovirus chorioretinitis in AIDS patients.

Authors:  J Gaub; A G Poulsen; C Pedersen; S Tinning; K Højgaard; M H Thomson; V Faber; J O Nielsen
Journal:  Scand J Infect Dis       Date:  1988

8.  Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro.

Authors:  E C Mar; Y C Cheng; E S Huang
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

9.  Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1.

Authors:  Y C Cheng; E S Huang; J C Lin; E C Mar; J S Pagano; G E Dutschman; S P Grill
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

10.  9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent.

Authors:  J C Martin; C A Dvorak; D F Smee; T R Matthews; J P Verheyden
Journal:  J Med Chem       Date:  1983-05       Impact factor: 7.446

View more
  5 in total

1.  Acyclovir, ganciclovir, and zidovudine transfer into rat milk.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  High-performance liquid chromatographic determination of 2',3'-didehydro-3'-deoxythymidine (d4T) in human and rabbit plasma and urine and its application to pharmacokinetic studies in the rabbit.

Authors:  S L Wong; R J Sawchuk
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

3.  Pharmacokinetics of ganciclovir and valganciclovir in the adult horse.

Authors:  R J Carmichael; C Whitfield; L K Maxwell
Journal:  J Vet Pharmacol Ther       Date:  2013-01-10       Impact factor: 1.786

4.  Comparative Pharmacokinetic Study for Linezolid and Two Novel Antibacterial Oxazolidinone Derivatives in Rabbits: Can Differences in the Pharmacokinetic Properties Explain the Discrepancies between Their In Vivo and In Vitro Antibacterial Activities?

Authors:  Mohsen A Hedaya; Vidhya Thomas; Mohamed E Abdel-Hamid; Elijah O Kehinde; Oludotun A Phillips
Journal:  Pharmaceutics       Date:  2017-09-07       Impact factor: 6.321

5.  c-di-GMP modulates type IV MSHA pilus retraction and surface attachment in Vibrio cholerae.

Authors:  Kyle A Floyd; Calvin K Lee; Wujing Xian; Mahmoud Nametalla; Aneesa Valentine; Benjamin Crair; Shiwei Zhu; Hannah Q Hughes; Jennifer L Chlebek; Daniel C Wu; Jin Hwan Park; Ali M Farhat; Charles J Lomba; Courtney K Ellison; Yves V Brun; Javier Campos-Gomez; Ankur B Dalia; Jun Liu; Nicolas Biais; Gerard C L Wong; Fitnat H Yildiz
Journal:  Nat Commun       Date:  2020-03-25       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.